Twist Bioscience Corporation (TWST) Identifies Competitive Antibodies for SARS-CoV-2
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Twist Bioscience Identifies Competitive Antibodies for SARS-CoV-2
May 6, 2020 8:00 AM EDTFunctional Antibodies Identified to S1 Spike Protein and ACE2 Cellular Receptor
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Twist Bioscience Corporation (Nasdaq: TWST) today reported it has identified competitive antibodies to SARS-CoV-2, the virus that causes COVID-19, which could potentially be used for diagnostic tests or therapeutic treatments. Twists unique monoclonal antibody candidates bind with high affinity to the receptor binding domain (RBD) on the S1 spike protein on the surface of SARS-CoV-2 viral molecules. Twist has also found antibody candidates that bind with high affinity... More
